Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

DCIS: Radiation Considerations

DCIS: Radiation Considerations Purpose of ReviewDuctal carcinoma in situ (DCIS) is commonly treated with radiotherapy as a part of breast-conserving therapy, though increasingly the use of routine radiation treatment is being questioned. The intent of this review is to summarize studies on the role of radiotherapy for DCIS, with an emphasis on more recent trials.Recent FindingsWhile older randomized clinical trials have established a local control benefit for adjuvant radiotherapy following breast-conserving surgery in all patients including those with low-risk DCIS, these and subsequent studies have failed to demonstrate any survival benefit. Given the risks associated with radiotherapy, studies have aspired to demonstrate that subgroups of DCIS patients who derive less benefit from treatment may safely avoid adjuvant radiotherapy. Nomograms based on retrospective analyses have been employed to help identify patients for omission of radiotherapy, and genomic assays as a proxy for tumor biology are being explored as strategies for patient selection. When patients do receive radiotherapy, radiation options such as hypofractionation, inclusion of a radiation boost to the resection cavity, and partial-breast irradiation are considerations to help individualize treatment. Finally, initial treatment for DCIS may have implications for subsequent therapy in the setting of salvage therapy for recurrent breast cancer.SummaryMore recent studies on DCIS have aimed at identifying subgroups of DCIS patients who may safely omit radiotherapy and strategies to individualize radiation treatment of DCIS. Radiotherapy for DCIS should be a decision made after a careful discussion between physicians and patients, taking into account individual patient characteristics and preferences. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Breast Cancer Reports Springer Journals

DCIS: Radiation Considerations

Loading next page...
 
/lp/springer-journals/dcis-radiation-considerations-9dsebGTxZ0
Publisher
Springer Journals
Copyright
Copyright © Springer Science+Business Media, LLC, part of Springer Nature 2020
ISSN
1943-4588
eISSN
1943-4596
DOI
10.1007/s12609-020-00357-0
Publisher site
See Article on Publisher Site

Abstract

Purpose of ReviewDuctal carcinoma in situ (DCIS) is commonly treated with radiotherapy as a part of breast-conserving therapy, though increasingly the use of routine radiation treatment is being questioned. The intent of this review is to summarize studies on the role of radiotherapy for DCIS, with an emphasis on more recent trials.Recent FindingsWhile older randomized clinical trials have established a local control benefit for adjuvant radiotherapy following breast-conserving surgery in all patients including those with low-risk DCIS, these and subsequent studies have failed to demonstrate any survival benefit. Given the risks associated with radiotherapy, studies have aspired to demonstrate that subgroups of DCIS patients who derive less benefit from treatment may safely avoid adjuvant radiotherapy. Nomograms based on retrospective analyses have been employed to help identify patients for omission of radiotherapy, and genomic assays as a proxy for tumor biology are being explored as strategies for patient selection. When patients do receive radiotherapy, radiation options such as hypofractionation, inclusion of a radiation boost to the resection cavity, and partial-breast irradiation are considerations to help individualize treatment. Finally, initial treatment for DCIS may have implications for subsequent therapy in the setting of salvage therapy for recurrent breast cancer.SummaryMore recent studies on DCIS have aimed at identifying subgroups of DCIS patients who may safely omit radiotherapy and strategies to individualize radiation treatment of DCIS. Radiotherapy for DCIS should be a decision made after a careful discussion between physicians and patients, taking into account individual patient characteristics and preferences.

Journal

Current Breast Cancer ReportsSpringer Journals

Published: Jun 18, 2020

There are no references for this article.